VahatiCor has enrolled the first U.S. patient in its SERRA-I early feasibility study of the A-FLUX Reducer System for coronary microvascular dysfunction.
The milestone brings the investigational device into U.S. clinical evaluation and builds on early human experience from SERRA-I, as well as ongoing enrolment in the SERRA-I European study. The first U.S. patient was enrolled at Yale-New Haven Hospital.
This is relevant because coronary microvascular dysfunction remains an underserved cardiovascular condition. Patients can experience persistent angina and related symptoms even when there are no blockages in the major coronary arteries. This can make diagnosis and treatment more difficult, particularly when conventional coronary disease pathways do not fully explain symptoms.
The A-FLUX Reducer System is a self-expanding nitinol implant delivered by catheter to the coronary sinus. It is designed to influence blood flow through the heart’s smaller vessels and address the underlying microvascular dysfunction.
VahatiCor describes the device as a self-expanding, repositionable coronary sinus reducer. It is currently under clinical evaluation and has not been approved by the U.S. FDA for commercial use.
SERRA-I is evaluating the initial use of the A-FLUX Reducer System in patients with symptomatic coronary microvascular dysfunction. The broader SERRA clinical programme includes centres across the United States and Europe, giving the company a pathway to gather early clinical experience across different care settings.
The study’s U.S. co-principal investigator is Samit Shah, MD, PhD, an interventional cardiologist at Yale New Haven Hospital Heart & Vascular Center and assistant professor of medicine at Yale School of Medicine. His involvement gives the programme an academic clinical anchor in a condition where evidence generation remains important.
The clinical need is significant because patients with coronary microvascular dysfunction may remain highly symptomatic despite standard therapy. VahatiCor noted that there is no approved option in the United States that directly targets microvascular disease, which creates a potential opportunity for device-based intervention if safety and efficacy are demonstrated.
Adoption will depend on the results of early feasibility and later-stage studies, procedural safety, durability of symptom benefit, physician training and how the device fits into diagnostic and treatment pathways for angina without obstructive coronary artery disease. Reimbursement will also be important because CMD is still under-recognised compared with obstructive coronary artery disease.
The development reflects a broader shift in interventional cardiology toward conditions beyond large-vessel obstruction. As clinicians better recognise microvascular disease as a contributor to angina and reduced quality of life, devices targeting smaller-vessel physiology may become a more active area of medtech development.
For VahatiCor, the first U.S. patient enrolment is an early but important step. The key question will be whether A-FLUX can generate enough clinical evidence to support a new interventional treatment category for patients whose symptoms are not addressed by existing therapies.
